Stacy Mullet, NP
Nurse Practitioner · Huntersville, NCNPI 1922071570
Payments from drug & device makers
Across 588 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$1K
- AstraZeneca$968
- Otsuka America Pharmaceutical, Inc.$734
- Pfizer$730
- Bayer$629
- plus $5K from 30 others
What the payments were for
- Food & beverage$10,591100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 81 | $1,534 |
| Novo Nordisk | 78 | $1,084 |
| AstraZeneca | 52 | $968 |
| Otsuka America Pharmaceutical, Inc. | 29 | $734 |
| Pfizer | 39 | $730 |
| Bayer | 36 | $629 |
| AbbVie | 34 | $604 |
| Boehringer Ingelheim | 29 | $501 |
| GSK | 20 | $454 |
| Axsome Therapeutics, Inc. | 20 | $422 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $362 |
| Amgen | 17 | $272 |
| Lundbeck LLC | 14 | $239 |
| Abbott | 12 | $236 |
| Amarin Pharma, Inc. | 11 | $203 |
| Idorsia Pharmaceuticals US Inc | 11 | $195 |
| Esperion Therapeutics, Inc. | 17 | $186 |
| Biohaven Pharmaceuticals, Inc. | 9 | $127 |
| Exact Sciences | 6 | $124 |
| Arbor Pharmaceuticals, Inc. | 6 | $121 |
| Astellas Pharma US Inc | 5 | $102 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $97 |
| Vanda Pharmaceuticals Inc. | 3 | $87 |
| Jazz Pharmaceuticals Inc. | 5 | $76 |
| Novartis | 3 | $71 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $70 |
| Neos Therapeutics, LP | 4 | $65 |
| Supernus Pharmaceuticals, Inc. | 4 | $58 |
| Dexcom, Inc. | 2 | $52 |
| Adlon Therapeutics L.p. | 3 | $51 |
| Azurity Pharmaceuticals, Inc. | 2 | $38 |
| Boston Scientific | 1 | $28 |
| Medicure Pharma Inc. | 1 | $22 |
| Tris Pharma Inc | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$112
How this compares
$10,591 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 81 | $102,139 |
| OzempicSemaglutide | 64 | $97,012 |
| JardianceEmpagliflozin | 61 | $82,180 |
| EliquisApixaban | 29 | $38,334 |
| Repatha SureclickEvolocumab | 37 | $35,867 |
| FarxigaDapagliflozin Propanediol | 21 | $31,353 |
| XareltoRivaroxaban | 21 | $24,323 |
| TrulicityDulaglutide | 14 | $19,794 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $14,689 |
| KerendiaFinerenone | 12 | $11,742 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,681 |
| Ropinirole ErRopinirole Hcl | 12 | $3,705 |
| Atorvastatin Calcium | 324 | $3,596 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 19 | $2,697 |
| Rosuvastatin Calcium | 250 | $2,524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,534 | $121,93395 claims |
| Novo NordiskOzempic | $1,084 | $97,01264 claims |
| Boehringer IngelheimJardiance | $501 | $82,18061 claims |
| PfizerEliquis | $730 | $38,33429 claims |
| AstraZenecaFarxiga | $968 | $31,35321 claims |
| GSKTrelegy Ellipta | $454 | $14,68919 claims |
| BayerKerendia | $629 | $11,74212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Huntersville
- Regina PlohalHuntersville$40K
- Jennifer HarrisHuntersville$18K
- Sandrivette JohnsonRaleigh$573K
- Skyler RogersPinehurst$174K
- Jamie DinerDurham$170K
- Ayeshia WrightMocksville$145K
- Deborah AllenDurham$112K
- Jeanann VawterGastonia$97K
- Terra KampJacksonville$72K
- Mary DilorenzoCharlotte$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.